阿司匹林剂量对磁悬浮左心室辅助装置血液相容性相关结局的影响:MOMENTUM 3研究分析
该研究为MOMENTUM 3试验的探索性分析,纳入321例HeartMate 3左心室辅助装置患者,比较常规剂量(325 mg)与低剂量(81 mg)阿司匹林联合目标INR 2.0-3.0抗凝的结局。2年无血液相容性相关不良事件生存率两组相似(43.4% vs 45.3%,p=0.94),出血与血栓事件也无差异。阿司匹林在HM3患者中的治疗作用尚待明确。
要点
- HM3患者中常规剂量与低剂量阿司匹林的2年无HRAE生存率相似。
- 两组无出血事件生存率与无血栓事件生存率均无显著差异。
- 阿司匹林在HM3患者中是否具有治疗获益尚待确定。
核心结论
- 在MOMENTUM 3试验的HM3左心室辅助装置患者中,常规剂量与低剂量阿司匹林表现出相似的出血和血栓事件发生率。
- 阿司匹林治疗在HM3左心室辅助装置患者中是否提供有意义的治疗效应仍有待确定。
研究设计与样本
- MOMENTUM 3研究(NCT02224755)的探索性分析,纳入321例HM3左心室辅助装置患者,分为常规剂量阿司匹林325 mg组(n=141)和低剂量阿司匹林81 mg组(n=180),均联合目标INR 2.0-3.0的抗凝治疗。
主要发现
- 2年无血液相容性相关不良事件生存率在常规剂量组与低剂量组相似(43.4% vs 45.3%,p=0.94)。
- 无出血事件生存率两组无差异(常规剂量54.4% vs 低剂量51.7%,p=0.42)。
- 无血栓事件生存率两组无差异(常规剂量76.8% vs 低剂量75.7%,p=0.92)。
- 常规剂量组患者较年轻(57±13 vs 60±12岁,p=0.035),且较少被指定为destination therapy(55% vs 67%,p=0.029)。
临床怎么用
- 对于HM3左心室辅助装置患者,低剂量阿司匹林(81 mg)与常规剂量(325 mg)在出血和血栓事件方面表现相似,但阿司匹林的治疗获益尚不明确,临床决策需个体化。
局限性
- 该分析为探索性分析,非随机对照设计,存在选择偏倚可能。
- 两组基线特征存在差异(年龄、destination therapy比例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aspirin (ASA) anti-platelet therapy is mandated with left ventricular assist devices (LVADs) to prevent hemocompatibility-related adverse events (HRAEs). However, the optimal dose of ASA with HeartMate 3 (HM3) LVAD is unknown. METHODS: In an exploratory analysis of HM3-supported patients in the MOMENTUM 3 study (NCT02224755), 2 groups were analyzed: usual-dose (325 mg) and low-dose (81 mg) ASA with anti-coagulation targeted to an international normalized ratio of 2.0 to 3.0. Exclusion criteria included patients not receiving either ASA 81 mg or 325 mg, those with HRAEs ≤7 days after device implantation, and those receiving >1 anti-platelet agent. The primary end-point was survival free from HRAEs (non-surgical bleeding, pump thrombosis, stroke, and peripheral arterial thromboembolic events) at 2 years. RESULTS: Overall, 321 HM3 patients (usual-dose: n = 141, low-dose: n = 180) were included in this analysis. Usual-dose group patients were younger (57 ± 13 vs 60 ± 12 years, p = 0.035) and less often assigned destination therapy (55% vs 67%, p = 0.029) than low-dose ASA. At 2 years, a similar proportion of patients in the usual- and low-dose groups (43.4% vs 45.3%, p = 0.94) met the primary end-point. There were no differences in survival free from hemorrhagic (usual-dose: 54.4% vs low-dose: 51.7%, p = 0.42) or thrombotic (usual-dose: 76.8% vs low-dose: 75.7%, p = 0.92) events. CONCLUSIONS: Usual- and low-dose ASA revealed similar rates of bleeding and thrombotic events in HM3 LVAD-supported patients within the MOMENTUM 3 trial. Whether ASA therapy provides any meaningful therapeutic effect in patients treated by the HM3 LVAD remains to be determined.
引用
- Saeed O, Colombo PC, Mehra MR, et al. Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study. J Heart Lung Transplant. 2020. PMID: 32340871. doi:10.1016/j.healun.2020.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。